Pmv Pharmaceuticals Stock Analysis
PMVP Stock | USD 1.59 0.02 1.24% |
Pmv Pharmaceuticals is undervalued with Real Value of 4.51 and Target Price of 13.2. The main objective of Pmv Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Pmv Pharmaceuticals is worth, separate from its market price. There are two main types of Pmv Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Pmv Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Pmv Pharmaceuticals is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Pmv Stock trading window is adjusted to America/New York timezone.
Pmv |
Pmv Stock Analysis Notes
About 81.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.42. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pmv Pharmaceuticals recorded a loss per share of 1.0. The entity had not issued any dividends in recent years. PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey. Pmv Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 54 people. To find out more about Pmv Pharmaceuticals contact David Mack at 609 642 6670 or learn more at https://www.pmvpharma.com.Pmv Pharmaceuticals Investment Alerts
Pmv Pharmaceuticals may become a speculative penny stock | |
Pmv Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (68.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Pmv Pharmaceuticals currently holds about 277.43 M in cash with (55.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Pmv Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Over 81.0% of the company shares are owned by institutional investors | |
Latest headline from news.google.com: PMV Pharmaceuticals files 200M mixed securities shelf - TipRanks |
Pmv Pharmaceuticals Upcoming and Recent Events
6th of March 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
6th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Pmv Largest EPS Surprises
Earnings surprises can significantly impact Pmv Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-11-12 | 2021-09-30 | -0.3 | -0.33 | -0.03 | 10 | ||
2022-03-01 | 2021-12-31 | -0.35 | -0.4 | -0.05 | 14 | ||
2024-05-09 | 2024-03-31 | -0.36 | -0.3 | 0.06 | 16 |
Pmv Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Goldman Sachs Group Inc | 2024-06-30 | 808.7 K | Millennium Management Llc | 2024-06-30 | 758.7 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 705.6 K | Personal Cfo Solutions, Llc | 2024-06-30 | 550.3 K | Citigroup Inc | 2024-09-30 | 514.9 K | Two Sigma Advisers, Llc | 2024-06-30 | 493.5 K | Two Sigma Investments Llc | 2024-09-30 | 483.1 K | Barclays Plc | 2024-06-30 | 465 K | Acuitas Investments, Llc | 2024-09-30 | 440.7 K | Orbimed Advisors, Llc | 2024-06-30 | 6.5 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 3.6 M |
Pmv Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 83.31 M.Pmv Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.27) | (0.29) | |
Return On Capital Employed | (0.34) | (0.35) | |
Return On Assets | (0.27) | (0.29) | |
Return On Equity | (0.31) | (0.29) |
Management Efficiency
Pmv Pharmaceuticals has return on total asset (ROA) of (0.2027) % which means that it has lost $0.2027 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2363) %, meaning that it created substantial loss on money invested by shareholders. Pmv Pharmaceuticals' management efficiency ratios could be used to measure how well Pmv Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/25/2024, Return On Tangible Assets is likely to drop to -0.29. In addition to that, Return On Capital Employed is likely to drop to -0.35. At this time, Pmv Pharmaceuticals' Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 11/25/2024, Non Current Liabilities Other is likely to grow to about 16.2 M, while Total Current Liabilities is likely to drop slightly above 9.2 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 4.70 | 2.91 | |
Tangible Book Value Per Share | 4.70 | 2.91 | |
Enterprise Value Over EBITDA | (1.58) | (1.66) | |
Price Book Value Ratio | 0.66 | 0.69 | |
Enterprise Value Multiple | (1.58) | (1.66) | |
Price Fair Value | 0.66 | 0.69 | |
Enterprise Value | 347.7 M | 330.3 M |
The leadership approach at Pmv Pharmaceuticals' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 1.484 | Return On Assets (0.20) | Return On Equity (0.24) |
Technical Drivers
As of the 25th of November, Pmv Pharmaceuticals holds the Risk Adjusted Performance of 0.0404, semi deviation of 2.01, and Coefficient Of Variation of 2288.02. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pmv Pharmaceuticals, as well as the relationship between them.Pmv Pharmaceuticals Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Pmv Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Pmv Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Pmv Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pmv Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pmv Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pmv Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pmv Pharmaceuticals Outstanding Bonds
Pmv Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pmv Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pmv bonds can be classified according to their maturity, which is the date when Pmv Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
US69354NAD84 Corp BondUS69354NAD84 | View | |
PRAA 8375 01 FEB 28 Corp BondUS69354NAE67 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
US69356NAA28 Corp BondUS69356NAA28 | View | |
PPL 739486 30 MAR 67 Corp BondUS69352PAC77 | View | |
PPL CAP FDG Corp BondUS69352PAL76 | View | |
PPG 12 15 MAR 26 Corp BondUS693506BU04 | View |
Pmv Pharmaceuticals Predictive Daily Indicators
Pmv Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pmv Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 17127.02 | |||
Daily Balance Of Power | (0.20) | |||
Rate Of Daily Change | 0.99 | |||
Day Median Price | 1.63 | |||
Day Typical Price | 1.62 | |||
Price Action Indicator | (0.05) | |||
Period Momentum Indicator | (0.02) | |||
Relative Strength Index | 71.88 |
Pmv Pharmaceuticals Forecast Models
Pmv Pharmaceuticals' time-series forecasting models are one of many Pmv Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pmv Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Pmv Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Pmv Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pmv shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pmv Pharmaceuticals. By using and applying Pmv Stock analysis, traders can create a robust methodology for identifying Pmv entry and exit points for their positions.
Last Reported | Projected for Next Year |
Current Pmv Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pmv analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pmv analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
13.2 | Strong Buy | 6 | Odds |
Most Pmv analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Pmv stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Pmv Pharmaceuticals, talking to its executives and customers, or listening to Pmv conference calls.
Pmv Stock Analysis Indicators
Pmv Pharmaceuticals stock analysis indicators help investors evaluate how Pmv Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Pmv Pharmaceuticals shares will generate the highest return on investment. By understating and applying Pmv Pharmaceuticals stock analysis, traders can identify Pmv Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 109.1 M | |
Total Stockholder Equity | 225.7 M | |
Capital Lease Obligations | 13.3 M | |
Property Plant And Equipment Net | 19 M | |
Cash And Short Term Investments | 203.1 M | |
Net Invested Capital | 225.7 M | |
Cash | 37.7 M | |
50 Day M A | 1.5758 | |
Net Interest Income | 9.8 M | |
Total Current Liabilities | 14 M | |
Investments | -24.7 M | |
Stock Based Compensation | 12.4 M | |
Common Stock Shares Outstanding | 48 M | |
Tax Provision | 3000.00 | |
Free Cash Flow | -56.6 M | |
Other Current Assets | 4.4 M | |
Accounts Payable | 3.2 M | |
Net Debt | -24.4 M | |
Depreciation | 1.3 M | |
Other Operating Expenses | 80.1 M | |
Non Current Assets Total | 44.7 M | |
Liabilities And Stockholders Equity | 252.2 M | |
Non Currrent Assets Other | 190 K |
Additional Tools for Pmv Stock Analysis
When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.